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Metformin: A stroke of luck 
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ABSTRACT 
Metformin is an oral glucose-lowering drug that has been widely used for more than half a century. Both the American Diabetes Association and the 
European Association for the study of Diabetes recommend metformin as the first line therapy for the treatment of type II diabetes mellitus. Metformin 
has considerably evolved from being an antidiabetic into a drug with a wider potential of therapeutic uses such as anticancer, antiaging, treatment of 
gestational hypertension, preeclampsia and weight loss. In addition to the in-label use of metformin as an anti-hyperglycemic medication, it is widely 
prescribed as an off label therapy for young women with Poly Cystic Ovary Syndrome for the treatment of symptoms associated with the disorder. 
This article is a brief summary that lists and briefly discusses current and potential non-hyperglycemic uses and effects of metformin. 
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INTRODUCTION 
Glucophage, literally glucose eater, is the name that the French Scientist Jean Sterne gave to metformin in the 1950s. 
Since then, the drug is used for the treatment of diabetes and it is the recommended first line treatment of type II 
diabetes mellitus. Traditionally, it is believed that metformin improves glycaemia by acting on the liver via AMPK 
activation. However, there is a growing evidence suggest that metformin has other target organs including the gut and 
intestines (1). 
In 2010, approximately 50 million metformin prescriptions were issued in the United Sates alone (2). While these 
prescriptions were not for diabetes only, the number is likely to increase as more uses of metformin are reported. For 
instance, numerous studies have indicated the potential and different uses of metformin including the 
treatment/prevention of several types of cancer, anti-ageing, cardiovascular protection, and neurological disorders (3). 
Also, various studies have indicated that long‑term administration of metformin reduces the risk of various types of 
cancer, including breast, colon and endometrial cancer, and glioma (4, 5). Furthermore, a number of studies showed that 
metformin can inhibit cell proliferation, induce cell death in various types of cancer cells, and increase the survival rate 
of diabetic patients with cancer (6). Currently, tens of clinical trials are undergoing to test various therapeutic potentials 
of metformin including trials that aim to investigate its potential anticancer activity against endometrial, prostate, 
pancreas, lung and breast cancer (1).  
The current uses of metformin, both in-label and off label, include antidiabetic and extends to anti-ageing as well. 
Therefore, listing all of the current and potential uses might not be feasible, however, the current manuscript is a review 
that lists and briefly discusses some of the different reported non-hyperglycemic clinical uses of metformin. 
METFORMIN AND CANCER 
People with diabetes have a mortality rate 3–4 times that of the general population (7) and an increased risk of several 
common cancers with an estimated incidence rate of about 1.2 times higher than that of non-diabetics (8, 9). However, 
a number of reports have suggested that metformin, which is frequently prescribed to reduce hepatic gluconeogenesis 
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and increase skeletal muscle glucose uptake in patients with type 2 diabetes could also potentially provide 
antiproliferative effects against several cancers (Figure 1).  
Evidence from in vitro, in vivo as well as epidemiological and observational studies suggest that metformin may not 
only prevent diabetes, but can actually be an important adjuvant for cancer therapy. Some of the published observational 
studies have reported a link between the use of metformin and reduced risk of cancers and cancer related deaths, 
including a study by Evans et al. which reported that metformin is associated with reduced risk of cancer in patients with 
type 2 diabetes and that the association appears to be in a dose-response relationship (4). Similarly, a retrospective study 
involving a diabetics cohort of more than 10,000 newly treated for type 2 diabetes and were followed for about 5 years, 
suggested that patients exposed to metformin were significantly less likely to have a cancer related death compared to 
diabetics on other treatments (10).  
Equally, a meta-analysis study in Taiwan that looked at the association between lung cancer and metformin treatment, 
concluded that the metformin use in type 2 diabetes patients may significantly reduce the risk of lung cancer, and that 
the antitumor protective mechanism of metformin was significantly higher for patients who used the drug for more than 
4 years (5). 
There is an increasing interest in studying the effect of metformin against different types of cancer. For example, a 
study by Li and colleagues reported a hospital-based case control study that investigated the effect of anti-diabetic 
therapies on pancreatic cancer. The authors suggested that diabetics who used metformin, particularly those who have 
prolonged usage (five or more years), had a reduced risk of pancreatic cancer compared to those who never used it (11). 
The study claimed that the risk of pancreatic cancer in metformin group was 62% lower than in the placebo group.  
A meta-analysis result from a systematic review of the effect of metformin use on various prostate cancer outcomes 
in patients with type 2 diabetes revealed that metformin use is associated with a 20% decrease in risk of recurrence in 
prostate cancer patients with concurrent type 2 diabetes (12). An observational study reported that metformin treatment 
was associated with an improved response among early stage breast cancer patients receiving neoadjuvant therapy, and 
that the drug was tested for its potential effect on breast cancer proliferation and follow up trials are planned (6).  
Furthermore, laboratory studies showed that metformin was able to inhibit cell proliferation, reduce colony formation, 
and cause partial cell cycle arrest in cancer cell lines (6). An in vitro study by Sabit et al., suggested that a cellular 
concentration of 100 mM of metformin resulted in more than 85% reduction in breast cancer (MCF-7) cell viability while 
treatment of colon cancer cells (CaCo-2) with a concentration of 5 mM was enough to achieve as high as 97% cell cancer 
mortality (13). The authors suggested that colorectal cancer cells were very sensitive to metformin even at low doses. 
Another in vitro study by Safari et al., reported that breast cancer cells treated with a cellular concentration of 10 mM of 
metformin resulted in the highest cellular apoptotic rate (14), which further confirms the sensitivity of cancer cells to 
metformin.  
 
Figure 1: Metformin and cancer prevention 
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One of the earliest in vivo studies that investigated the anti-tumorigenesis effect of metformin was reported by Rattan 
et al. (15). They described the effect of metformin enhanced cisplatin on ovarian cancer model using IP-induced A2780 
xenograft in nude female mice. The study reported a number of interesting findings including xenografts treated with 
metformin showed reduced tumor burden, reduced angiogenesis, and metastatic potentials compared with untreated 
mice (15).  
MECHANISM OF ACTION OF ANTICANCER ACTIVITY 
Metformin’s anti-tumorigenesis mechanism of action are not fully understood as to whether metformin acts directly 
on the growing tumor, or is the effect due its ability to change host physiology or both of these mechanisms combined. 
However, a number of studies have suggested several different mechanisms for example, a study by Li and colleagues 
postulated that the anticancer effect of metformin occurs both at the cellular and at the organism levels simultaneously 
(11).  
We believe that this hypothesis may in part be true, but given the fact that metformin was reported to effect specific 
type of cancers and not others may suggest that its activity is likely achieved on a cellular level rather than organism.  
Several studies reported possible mechanisms of action of antitumor activity of metformin, including the suppression 
of cancer cell metabolism (16), inhibition of mammalian target of rapamycin (mTOR) (1), tumor angiogenesis inhibition 
(16), immunomodulation such as increasing the number of CD8+ tumor-infiltrating lymphocytes (17, 18), and activation 
of tumor apoptosis and autophagy (19).  
However, in vivo studies show that metformin has a reduced antitumor activity on control diet mice than it does on 
a high-energy diet mice associated with hyperinsulinemia and accelerated tumor growth (20), indicating that the insulin 
reducing action of metformin may contribute to its antitumor activity, and that it may have less effect on cancers in less 
hyperinsulinemic patients (6).  
Therefore, based on the reported mechanisms of action of metformin, its different pharmacological efficacy and 
multiple target sites, we can speculate that the antineoplastic activity of metformin is more likely to be an outcome of a 
collective simultaneous mechanisms primarily through its activity on hyperglycemia. 
CARDIOVASCULAR PROTECTIVE EFFECT 
While reducing glucose level may not necessarily reduce cardiovascular events (21), surely, the effect of metformin 
on glycemic control will result either directly or indirectly in improved macrovascular protection. Numerous studies have 
shown the beneficial effect of metformin on cardiovascular including; a trial involving type 2 diabetic patients who 
received a three months therapy of metformin treatment compared to placebo, which showed that the metformin treated 
group displayed improved endothelium-dependent vascular responses, whereas vascular responses of patients treated 
with placebo remained unchanged (22, 23). Also, patients with ischemic cardiomyopathy, who were treated with 
metformin had reduced rates of re-infarction, occurrence of angina pectoris, and acute coronary (24). Additionally, 
metformin treated patients showed improved endothelial function (25) and in vitro studies reported that metformin has 
a direct protective action on the vascular endothelium (26). 
The exact mechanism of how metformin exerts its protective cardiovascular mechanisms remains unsolved with 
various possible mechanisms were reported; including that metformin treatment will lead to improvement in coagulation, 
oxidative stress (27), endothelial dysfunction (26, 27), and inflammatory pathway (24). 
POLYCYSTIC OVARY SYNDROME 
Polycystic ovary syndrome (PCOS) is a complex metabolic disorder and the most common endocrine disorder in 
reproductive-age women that affects between 5-20% of this age group (28). The clinical expression of PCOS varies but 
commonly includes oligo-ovulation or anovulation, hyperandrogenism (either clinical or biochemical), and the presence 
of polycystic ovaries (29). Typically, patients may present with a combination of hyperandrogenism symptoms, menstrual 
irregularities, metabolic syndrome, infertility, acne, and obesity (30).  
While there is no available treatment for PCOS, different therapies have been used to improve the symptoms 
associated with PCOS, including metformin, which has been recognized as the most preferred treatment modality for 
PCOS (Figure 2). While, the exact mechanism of action of metformin in patients with PCOS remain unknown, it has been 
extensively prescribed for child-bearing age women with PCOS.  
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One possible mechanism of action of how metformin improves PCOS symptoms is thought to be through its effect 
on reducing the circulating levels of androgens and body weight, which eventually manages the symptoms and cysts 
(31). Lowering the circulating levels of androgen will lead to the alleviation of other PCOS symptoms such as relief in 
acne and hirsutism, improvement in the occurrence of mood swings, reduction/resolution of menstrual irregularities, 
and enhancement of ovulation (32).  
Also, insulin resistance and the associated compensatory hyperinsulinaemia, are likely to be an important contributing 
factor in the pathogenesis of PCOS, thus metformin and other insulin-sensitizing drugs were introduced as a treatment 
option (33). 
Furthermore, metformin produces a general action on glucose regulation metabolism by insulin (34), and insulin 
resistance values are good predictors of the efficacy of metformin treatment (35), suggesting that metformin might act 
to induce ovulation as a result of the improved metabolic control.  
Moreover, it was reported that women with PCOS are at higher risk of miscarriage in the early months of pregnancy 
as are women without PCOS (36, 37). While there are conflicting results in the use of metformin during pregnancy, some 
research shows that metformin may reduce the risk of miscarriage in pregnant women with PCOS without an increase in 
the rate of fetal malformation (35, 36). The findings of a meta-analysis by Cassina et al. that was based on metformin 
exposure in 351 women with PCOS indicated that there is no increase in congenital anomaly with metformin use in 
pregnancy (38).  
Furthermore, analyses of nine randomized trials including 816 women with PCOS by Lo et al, reported that metformin 
increased clinical pregnancy rates and decreased the risk of ovarian hyperstimulation syndrome (39). Likewise, the use 
of metformin throughout pregnancy in women with polycystic ovary syndrome decreases the rates of early pregnancy 
loss and preterm labor; hence protecting against fetal growth restriction (34).  
Several animal studies found that metformin might stimulate ATP production, which serve as an important source of 
energy for the growing oocyte (40). Another in vivo study by Martin et al., suggested that metformin leads to an increase 
usage of lipids and β-oxidation of fatty acids that serve as an energy source for oocyte maturation and early embryo 
development (41). Additional protective effect of metformin on embryo development was reported by Huang et al., 
which suggested that metformin use by Dehydroepiandrosterone treated mice, which resemble some characters of 
human PCOS, such as irregular sexual cycles and polycystic ovaries, showed reduced oxidative stress and increase 
antioxidant defense in oocytes (42). 
 
Figure 2: Off-label usage of Metformin 
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MISCELLANEOUS 
Several studies have been reported the off-label usage of metformin in different clinical settings (Figure 2). As we 
mentioned above, metformin was found to be effective in managing various symptoms related to PCOS including; 
oligomenorrhea; and the prevention of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization 
(IVF)/intracytoplasmic sperm injection (43). However, in some cases, such as hirsutism caused by PCOS and anovulatory 
infertility in women with PCOS, the routine use of metformin less favored due to lack of supportive evidence (43, 44). 
Furthermore, there is insufficient evidence that metformin may induce ovulation; prevent miscarriage, multiple 
gestations, and pregnancy complications (e.g. prevention of spontaneous abortion and gestational diabetes) in women 
with PCOS (45).  
Recently, the American Diabetes Association guidelines suggested metformin therapy could be used for the 
prevention of type 2 diabetes in patients with prediabetes, with BMI ≥35 kg/m2, aged <60 years, and women with prior 
gestational diabetes mellitus (46).  
Metformin was found to be clinically effective in the treatment of obesity, obesity related insulin resistance and 
metabolic syndrome due to antipsychotic-induced weight gain (47). Other observed uses of metformin include antiaging, 
anti-inflammatory and cardio-protective effects were reported in several studies, which need to be further confirmed in 
randomized clinical trials (48). 
CONCLUSION 
There is an increasing interest in the use of metformin as a potential treatment for different types of cancer. The 
widely used and well tolerated drug was reported in observational, laboratory and animal studies to have some 
antineoplastic activities through not yet known mechanisms. In this review, we reported some of the current and potential 
non-hyperglycemic uses of metformin. If proven, the reasonably safe and affordable metformin would make an ideal 
anticancer agent that can be used as an adjuvant to standard treatment, a monotherapy, or combined with other 
chemotherapeutics for the treatment of cancer. 
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